Aktis Oncology, Inc.

AKTSUnited States

8 filed reports · 159 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

—

Net income

-$44M

12 months to 2024-12-31 · to Dec 31, 2024

a year earlier: -$28.6M

Filed report

Operating income

—

Latest quarter

Revenue

$3.91M

Q3 FY2026 · to Sep 30, 2026

up +147% vs $1.58M

10-Q

Net income

-$29.9M

Q3 FY2026 · to Sep 30, 2026

a year earlier: -$15.5M

10-Q

Operating income

-$34.7M

Q3 FY2026 · to Sep 30, 2026

a year earlier: -$18.2M

10-Q

Filed reports

8 reports · Jan 2026 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 22 earnings-release figures, 83 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR4636Mar 2026 to Sep 2026
Registration · S-1/ASEC EDGAR28Jan 2026
Current · 8-KSEC EDGAR11Sep 2026
Registration · 424B4SEC EDGAR156Jan 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q38-K2026-09-302026-11-121Open
FY2026 Q310-Q2026-09-302026-11-12290Open
FY2026 Q210-Q2026-06-302026-08-13166Open
FY2026 Q110-Q2026-03-312026-05-111Open
FY2026 Q110-Q2026-03-312026-05-11179Open
FY2026424B42026-01-092026-01-0956Open
FY2026S-1/A2026-01-072026-01-074Open
FY2026S-1/A2026-01-052026-01-054Open

Financial data

159 concepts · 701 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial140 concepts · 660 facts · Dec 2023 to Sep 2026

  • Cash and cash equivalents at carrying value8 · Mar 2025 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents8 · Mar 2025 to Sep 2026
  • Restricted cash equivalents noncurrent8 · Mar 2025 to Sep 2026
  • Stockholders equity (US GAAP)8 · Mar 2025 to Sep 2026
  • Accrued expenses and other current liabilities6 · Mar 2025 to Sep 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value6 · Mar 2025 to Sep 2026
  • Amortization of financing costs and discounts6 · Mar 2025 to Sep 2026
  • Capital expenditures incurred but not yet paid6 · Mar 2025 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations6 · Mar 2025 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect continuing operations6 · Mar 2025 to Sep 2026
  • Comprehensive income net of tax attributable to noncontrolling interest6 · Mar 2025 to Sep 2026
  • Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering6 · Mar 2025 to Sep 2026
  • Deferred Offering Costs Included In Accrued Expenses6 · Mar 2025 to Sep 2026
  • Deferred offering costs transferred to additional paid in capital6 · Mar 2025 to Sep 2026
  • Depreciation6 · Mar 2025 to Sep 2026
  • Depreciation depletion and amortization6 · Mar 2025 to Sep 2026
  • Earnings per share basic6 · Mar 2025 to Sep 2026
  • Earnings per share diluted6 · Mar 2025 to Sep 2026
  • General and administrative expense (US GAAP)6 · Mar 2025 to Sep 2026
  • Increase decrease in accounts payable6 · Mar 2025 to Sep 2026
  • Increase decrease in deferred revenue6 · Mar 2025 to Sep 2026
  • Increase decrease in interest and dividends receivable6 · Mar 2025 to Sep 2026
  • Increase decrease in operating lease liability6 · Mar 2025 to Sep 2026
  • Increase decrease in other noncurrent assets6 · Mar 2025 to Sep 2026

Offering Terms16 concepts · 23 facts · Jan 2026

  • Securities Offered by Company3 · Jan 2026
  • Underwriters Option Securities3 · Jan 2026
  • Offering Price Range High2 · Jan 2026
  • Offering Price Range Low2 · Jan 2026
  • Planned Use of Offering Proceeds2 · Jan 2026
  • Dilution per Security to New Investors1 · Jan 2026
  • Lock-Up Period Days1 · Jan 2026
  • Net Tangible Book Value per Security After Offering1 · Jan 2026
  • Net Tangible Book Value per Security Before Offering1 · Jan 2026
  • Offering Gross Proceeds1 · Jan 2026
  • Offering Net Proceeds1 · Jan 2026
  • Offering Price per Security1 · Jan 2026
  • Offering Proceeds Before Expenses per Security1 · Jan 2026
  • Offering Proceeds Before Expenses to Company1 · Jan 2026
  • Underwriting Discount per Security1 · Jan 2026
  • Underwriting Discount Total1 · Jan 2026

Segment3 concepts · 18 facts · Mar 2025 to Sep 2026

  • Net income loss6 · Mar 2025 to Sep 2026
  • Revenue from collaborative arrangement excluding revenue from contract with customer6 · Mar 2025 to Sep 2026
  • Segment reporting other item amount6 · Mar 2025 to Sep 2026

Segments

18 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 18 facts

  • Reportable Segment Aggregation Before Other Operating18 · Mar 2025 to Sep 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary66 claims from 4 reports · Mar 2026 to Sep 2026
  • Management discussion (MD&A) commentary85 claims from 5 reports · Dec 2025 to Sep 2026
  • Risk-factor changes9 claims from 1 report · Dec 2025
  • Risk factors187 risks from 2 annual reports · 2025

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Aktis Oncology, Inc. (AKTS) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

Aktis Oncology, Inc. (AKTS): 12 months to 2024-12-31 net income -$44M · FactIQ